| P – Under 60-year-old patients undergoing induction treatment for AML |
| I – Daunorubicin (45, 60 or 90 mg/m2/day) |
| C – Daunorubicin (45, 60 or 90 mg/m2/day) |
| O – Complete remission rate, overall survival, and disease-free survival |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.